ROCKLAND, Mass.--(BUSINESS WIRE)--BioSphere Medical, Inc. (NASDAQ: BSMD), a medical device company that has pioneered the use of bioengineered microspheres to treat uterine fibroids, hypervascularized tumors, and vascular malformations by a minimally invasive, image-guided medical procedure called embolotherapy, today announced that the Company will sponsor a symposium at the AAGL 37th Global Congress of Minimally Invasive Gynecology on October 30 in Las Vegas at the Paris Las Vegas Hotel. The Symposium topic is “Successful Collaboration for the Latest Treatments of Fibroids.” Also, on October 29, the treatment of fibroids will be further discussed in a post graduate course, chaired by Dr. Linda Bradley, Vice-Chair, Department of Obstetrics and Gynecology, and Director, Center for Menstrual Disorders, Fibroids & Hysteroscopic Services, The Cleveland Clinic, which includes as a learning objective the creation of a “successful collaborative practice with radiologists for uterine fibroid embolization (UFE).”
